Clinical Trials Logo

Clinical Trial Summary

This study is designed to investigate the safety profile and the photoirritant potential of eltrombopag in healthy subjects. The study is placebo- and positive controlled, randomized, parallel group with three treatment arms: eltrombopag (75 mg QD), placebo, and a positive control (ciprofloxacin, 500 mg BID). Eltrombopag will be administered in a double-blind fashion with respect to placebo and the positive control, ciprofloxacin, will be administered under observer-blinded conditions. Twelve to fifteen subjects will be recruited into each arm, to assure total enrollment of 36 evaluable subjects. The primary endpoint is the photosensitizing potential of eltrombopag as measured by photoirritant index (PI) and change in minimum erythemal dose (MED) in comparison with placebo.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00688272
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date June 2, 2008
Completion date September 25, 2008

See also
  Status Clinical Trial Phase
Completed NCT00908037 - Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT00442871 - Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment Phase 1
Completed NCT01098487 - A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Phase 4
Withdrawn NCT01440361 - A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. Phase 2
Completed NCT01064336 - Promacta Pregnancy Registry N/A
Completed NCT00424177 - Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT) Phase 2
Completed NCT00351468 - EXTEND (Eltrombopag Extended Dosing Study) Phase 3
Completed NCT01072162 - Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect Phase 1
Completed NCT00643929 - LENS - Long-term Eltrombopag Observational Study N/A
Completed NCT00102739 - SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) Phase 2
Completed NCT01416311 - Drug Use Investigation for REVOLADE (ITP)
Completed NCT00359463 - Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment Phase 1